CUTIA THERAPEUTICS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.7 HKD | +4.76% |
|
+9.84% | -29.87% |
| Apr. 30 | Cutia Therapeutics' Unit Receives Jiangsu Drug Manufacturing Certificate | MT |
| Apr. 30 | Cutia Therapeutics Submits NDA for Androgenetic Alopecia Treatment Spray; Shares Jump 6% | MT |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 3,034 | 2,073 | - | - |
| Enterprise Value (EV) 1 | 3,034 | 2,296 | 2,156 | 2,500 |
| P/E ratio | -1.04 x | -4.26 x | -5.38 x | -13.3 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 22 x | 7.36 x | 4.25 x | 2.21 x |
| EV / Revenue | 22 x | 8.15 x | 4.42 x | 2.66 x |
| EV / EBITDA | -6.09 x | -5.08 x | -6.39 x | -19.1 x |
| EV / FCF | - | -4.34 x | -7.31 x | -8.5 x |
| FCF Yield | - | -23.1% | -13.7% | -11.8% |
| Price to Book | - | 2.39 x | 4.24 x | 5.67 x |
| Nbr of stocks (in thousands) | 304,024 | 304,739 | - | - |
| Reference price 2 | 9.980 | 6.804 | 6.804 | 6.804 |
| Announcement Date | 3/27/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 137.6 | 281.7 | 487.5 | 940 |
| EBITDA 1 | - | -498 | -451.7 | -337.4 | -131 |
| EBIT 1 | - | -538.9 | -495 | -382.9 | -201.5 |
| Operating Margin | - | -391.58% | -175.74% | -78.54% | -21.44% |
| Earnings before Tax (EBT) 1 | - | -1,964 | -486.3 | -384.9 | -183 |
| Net income 1 | -555.8 | -1,964 | -486.3 | -384.9 | -156 |
| Net margin | - | -1,426.91% | -172.66% | -78.95% | -16.6% |
| EPS 2 | -6.940 | -9.600 | -1.597 | -1.265 | -0.5100 |
| Free Cash Flow 1 | - | - | -529.5 | -295 | -294 |
| FCF margin | - | - | -187.99% | -60.51% | -31.28% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - |
| Announcement Date | 5/30/23 | 3/27/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | 223 | 82.8 | 427 |
| Net Cash position 1 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | -0.4937 x | -0.2455 x | -3.26 x |
| Free Cash Flow 1 | - | - | -530 | -295 | -294 |
| ROE (net income / shareholders' equity) | - | - | -48.2% | -62.1% | -35.7% |
| ROA (Net income/ Total Assets) | - | - | -30.3% | -22.8% | -9.5% |
| Assets 1 | - | - | 1,608 | 1,686 | 1,642 |
| Book Value Per Share 2 | - | - | 2.840 | 1.610 | 1.200 |
| Cash Flow per Share 2 | - | - | -1.760 | -0.9600 | -0.7000 |
| Capex 1 | - | - | 83.3 | 75.9 | 56 |
| Capex / Sales | - | - | 29.59% | 15.56% | 5.96% |
| Announcement Date | 5/30/23 | 3/27/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
6.804
CNY
Average target price
16.85
CNY
Spread / Average Target
+147.68%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -29.87% | 287M | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +13.62% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- 2487 Stock
- Financials Cutia Therapeutics
